Botanicals ZP-118

Does ashwagandha in a drink actually have any effect?

Ashwagandha (Withania somnifera, primarily as KSM-66 extract) has genuine, well-replicated clinical evidence for reducing cortisol levels, improving perceived stress, and supporting sleep quality — but exclusively at doses of 300–600 mg/day consumed consistently over 8–12 weeks. A single drink containing 50–150 mg of ashwagandha (the typical commercial range) will not produce a measurable cortisol or stress effect. Ashwagandha has no documented acute single-dose effect that would be relevant to a drink consumed once.

The pharmacology of ashwagandha's adaptogenic effects is reasonably well characterised. The primary active compounds are withanolides — steroidal lactones unique to Withania species, primarily withaferin A and withanolide D. These compounds interact with the HPA (hypothalamic-pituitary-adrenal) axis, the body's central stress response system, reducing the secretion of cortisol and corticosterone over time through mechanisms that appear to involve modulation of the stress protein HSP70 and suppression of nuclear factor NF-κB activation.

The KSM-66 extract standardised to ≥5% withanolides from Ixoreal Biomed is the form used in most published clinical trials — including the most-cited 2012 trial in the Indian Journal of Psychological Medicine (64 subjects, 300 mg/day KSM-66 for 60 days, significant reduction in serum cortisol and PSS stress scores versus placebo) and a 2019 Medicine trial showing improved sleep quality. The effect size is meaningful at therapeutic doses: 28% reduction in morning cortisol in some studies.

The problem for drinks: these effects accumulate over weeks of daily supplementation. There is no published evidence of an acute single-dose effect — the mechanism requires consistent withanolide intake to progressively modulate the HPA axis. A drink consumed once delivers at best 10–30% of the minimum studied dose of the relevant extract form, and even a full dose would need to be consumed daily for 8+ weeks before any measurable effect could be expected.

Commercially, ashwagandha is often included in NA drinks at sub-therapeutic doses because: (1) it passes toxicology review easily (very safe at all commercially used doses), (2) it has high consumer recognition, (3) it provides a differentiation claim on the label. The experienced consumer or buyer should understand this context when evaluating functional claims.

ParameterClinical standardTypical drink doseGap assessment
Extract formKSM-66 (≥5% withanolides)Often unstatedUnknown (critical)
Daily dose300–600 mg/day50–150 mg/serve2–10× below clinical
Duration8–12 weeks minimumSingle drinkNot applicable
Effect timelineGradual (weeks)Immediate use expectedMismatch

Zeroproof.one's guide to functional NA drinks includes a honest assessment of ashwagandha, rhodiola, and other adaptogens — rated by their evidence quality and realistic dose relevance in commercial drinks.